These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 32679525)

  • 21. Prognostic relevance of the C-X-C motif chemokine ligand 13 and interleukin-8 in predicting the transition from clinically isolated syndrome to multiple sclerosis.
    Klíčová K; Mareš J; Sobek O; Rous Z; Rous M; Raška M; Hartung HP
    Eur J Neurosci; 2024 Jun; 59(11):2955-2966. PubMed ID: 38453679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
    Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
    Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chitinase-3-like 1-protein in CSF: a novel biomarker for progression in patients with multiple sclerosis.
    Talaat F; Abdelatty S; Ragaie C; Dahshan A
    Neurol Sci; 2023 Sep; 44(9):3243-3252. PubMed ID: 36988727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of Chitinase 3-like 1 as a Biomarker in Multiple Sclerosis: A Systematic Review and Meta-analysis.
    Floro S; Carandini T; Pietroboni AM; De Riz MA; Scarpini E; Galimberti D
    Neurol Neuroimmunol Neuroinflamm; 2022 Jul; 9(4):. PubMed ID: 35534236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sulfatide isoform pattern in cerebrospinal fluid discriminates progressive MS from relapsing-remitting MS.
    Novakova L; Singh AK; Axelsson M; Ståhlman M; Adiels M; Malmeström C; Zetterberg H; Borén J; Lycke J; Cardell SL; Blomqvist M
    J Neurochem; 2018 Aug; 146(3):322-332. PubMed ID: 29676479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone.
    Öhrfelt A; Axelsson M; Malmeström C; Novakova L; Heslegrave A; Blennow K; Lycke J; Zetterberg H
    Mult Scler; 2016 Oct; 22(12):1587-1595. PubMed ID: 26754805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers.
    Ottervald J; Franzén B; Nilsson K; Andersson LI; Khademi M; Eriksson B; Kjellström S; Marko-Varga G; Végvári A; Harris RA; Laurell T; Miliotis T; Matusevicius D; Salter H; Ferm M; Olsson T
    J Proteomics; 2010 Apr; 73(6):1117-32. PubMed ID: 20093204
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis.
    Novakova L; Axelsson M; Malmeström C; Zetterberg H; Björkhem I; Karrenbauer VD; Lycke J
    J Neurol Sci; 2015 Nov; 358(1-2):201-6. PubMed ID: 26342940
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosis.
    Augutis K; Axelsson M; Portelius E; Brinkmalm G; Andreasson U; Gustavsson MK; Malmeström C; Lycke J; Blennow K; Zetterberg H; Mattsson N
    Mult Scler; 2013 Apr; 19(5):543-52. PubMed ID: 23069872
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Score Based on NfL and Glial Markers May Differentiate Between Relapsing-Remitting and Progressive MS Course.
    Huss A; Otto M; Senel M; Ludolph AC; Abdelhak A; Tumani H
    Front Neurol; 2020; 11():608. PubMed ID: 32765393
    [No Abstract]   [Full Text] [Related]  

  • 31. Monocyte and Lymphocyte Activation and Regulation in Multiple Sclerosis Patients. Therapy Effects.
    González-Oria MC; Márquez-Coello M; Girón-Ortega JA; Argente J; Moya M; Girón-González JA
    J Neuroimmune Pharmacol; 2019 Sep; 14(3):413-422. PubMed ID: 30649665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes.
    Cantó E; Tintoré M; Villar LM; Costa C; Nurtdinov R; Álvarez-Cermeño JC; Arrambide G; Reverter F; Deisenhammer F; Hegen H; Khademi M; Olsson T; Tumani H; Rodríguez-Martín E; Piehl F; Bartos A; Zimova D; Kotoucova J; Kuhle J; Kappos L; García-Merino JA; Sánchez AJ; Saiz A; Blanco Y; Hintzen R; Jafari N; Brassat D; Lauda F; Roesler R; Rejdak K; Papuc E; de Andrés C; Rauch S; Khalil M; Enzinger C; Galimberti D; Scarpini E; Teunissen C; Sánchez A; Rovira A; Montalban X; Comabella M
    Brain; 2015 Apr; 138(Pt 4):918-31. PubMed ID: 25688078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cerebrospinal fluid NCAM levels are modulated by disease-modifying therapies.
    Axelsson M; Dubuisson N; Novakova L; Malmeström C; Giovannoni G; Lycke J; Gnanapavan S
    Acta Neurol Scand; 2019 May; 139(5):422-427. PubMed ID: 30657162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elevation of cerebrospinal fluid soluble CD27 levels in patients with meningeal localization of lymphoid malignancies.
    Kersten MJ; Evers LM; Dellemijn PL; van den Berg H; Portegies P; Hintzen RQ; van Lier RA; von dem Borne AE; van Oers RH
    Blood; 1996 Mar; 87(5):1985-9. PubMed ID: 8634448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of candidate biomarkers in converting and non-converting clinically isolated syndrome by proteomics analysis of cerebrospinal fluid.
    Timirci-Kahraman O; Karaaslan Z; Tuzun E; Kurtuncu M; Baykal AT; Gunduz T; Tuzuner MB; Akgun E; Gurel B; Eraksoy M; Kucukali CI
    Acta Neurol Belg; 2019 Mar; 119(1):101-111. PubMed ID: 29873030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interleukin-12p40 in the spinal fluid as a biomarker for clinically isolated syndrome.
    Orbach R; Gurevich M; Achiron A
    Mult Scler; 2014 Jan; 20(1):35-42. PubMed ID: 23722323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cerebrospinal fluid sulfatide isoforms lack diagnostic utility in separating progressive from relapsing-remitting multiple sclerosis.
    Novakova L; Henricsson M; Björnson E; Axelsson M; Borén J; Rosenstein I; Lycke J; Cardell SL; Blomqvist M
    Mult Scler Relat Disord; 2023 Jun; 74():104705. PubMed ID: 37060853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fatigue scores correlate with other self-assessment data, but not with clinical and biomarker parameters, in CIS and RRMS.
    Håkansson I; Johansson L; Dahle C; Vrethem M; Ernerudh J
    Mult Scler Relat Disord; 2019 Nov; 36():101424. PubMed ID: 31586802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deregulation of microRNA-181c in cerebrospinal fluid of patients with clinically isolated syndrome is associated with early conversion to relapsing-remitting multiple sclerosis.
    Ahlbrecht J; Martino F; Pul R; Skripuletz T; Sühs KW; Schauerte C; Yildiz Ö; Trebst C; Tasto L; Thum S; Pfanne A; Roesler R; Lauda F; Hecker M; Zettl UK; Tumani H; Thum T; Stangel M
    Mult Scler; 2016 Aug; 22(9):1202-14. PubMed ID: 26493127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis.
    Novakova L; Axelsson M; Khademi M; Zetterberg H; Blennow K; Malmeström C; Piehl F; Olsson T; Lycke J
    Mult Scler; 2017 Jan; 23(1):62-71. PubMed ID: 27003946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.